Author details

Full Name

Weike Bao

Affiliation

ORCID

Career Start Year

1999

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
28523109	Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.	ACS Medicinal Chemistry Letters	2017
28487390	Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.	J Am Heart Assoc	2017
26098939	Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart.	PLoS ONE	2015
23449942	Examining the relationship between exercise tolerance and isoproterenol-based cardiac reserve in murine models of heart failure.	Journal of Applied Physiology	2013
24125539	Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.	Cardiovascular Diabetology	2013
24348421	Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury.	Frontiers in Pharmacology	2013
21671268	Serial MRI characterization of the functional and morphological changes in mouse lung in response to cardiac remodeling following myocardial infarction.	Magnetic Resonance in Medicine	2012
23136043	An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.	Science Translational Medicine	2012
21887274	Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.	PLoS ONE	2011
20714241	Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.	Journal of Cardiovascular Pharmacology	2010
18499744	Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2.	Journal of Pharmacology and Experimental Therapeutics	2008
18287212	In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats.	Journal of Pharmacology and Experimental Therapeutics	2008
17577100	Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.	Journal of Cardiovascular Pharmacology	2007
17704827	The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.	British Journal of Pharmacology	2007
15677515	Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.	Diabetes	2005
14962485	Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.	Cardiovascular Research	2004
15761951	Simultaneous assessment of left-ventricular infarction size, function and tissue viability in a murine model of myocardial infarction by cardiac manganese-enhanced magnetic resonance imaging (MEMRI).	NMR in Biomedicine	2004
14557369	Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury.	Circulation	2003
11812160	Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte.	Journal of Molecular and Cellular Cardiology	2002
12031700	Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9.	Cardiovascular Research	2002
11273734	Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning.	Journal of Molecular and Cellular Cardiology	2001
11714655	In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.	Circulation	2001
11192369	Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice.	Basic Research in Cardiology	2000
10500207	The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene.	Proc Natl Acad Sci U S A	1999